Oncology--Improving Advanced Prostate Cancer Management in Latin America

Overview

This RFP is to provide financial support to organizations to host and coordinate a two-day medical education program at the organization, to be led by two international Visiting Professors with expertise matched to the organization’s unmet educational needs surrounding the management of advanced prostate cancer. Healthcare practitioners, researchers and patients will benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible.

Our support to this first-time competitive VP Program for Latin America, reflects our commitment to improve outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and education for healthcare professionals in Latin America.

The goals of this program are to provide meaningful practice-based educational experiences for oncology-care teams in Latin America, building capacity in Latin American cancer medicine by identifying gaps in patient care and assisting with solutions, and building global collaborations between Latin American and Western oncology care professionals.

Eligibility

_We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's [website]().
_

Application Details

The Prostate Cancer Foundation (PCF) and Pfizer Inc.
Independent Medical Education
Improving Advanced Prostate Cancer
Management in Latin America
Visiting Professorship Program
Request for Proposals (RFP)
I. Background
About the Prostate Cancer Foundation
The Prostate Cancer Foundation (PCF) is the world’s leading philanthropic organization dedicated to funding life-
saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has been responsible for raising more than
$1 billion in support of cutting-edge research by more than 2,250 research projects at 245 leading cancer centers,
with a global footprint spanning 28 countries. Since PCF’s inception, and through its efforts, patients around the
world are living longer, suffering fewer complications, and enjoying better quality of life. PCF is committed to creating
a global public square for prostate cancer, in service to our mission of ending death and suffering from the disease.
Learn more at pcf.org.
About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g.,
research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are
aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly
posted RFP that provides detail regarding a specific area of interest, sets timelines for review and approval, and
uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application
addressing the specific gaps in research, practice or care as outlined in the specific RFP.
About the Visiting Professorship (VP) Program
This RFP is to provide financial support to organizations to host and coordinate a two-day medical education
program at the organization, to be led by two international Visiting Professors with expertise matched to the
organization’s unmet educational needs surrounding the management of advanced prostate cancer. Healthcare
practitioners, researchers and patients will benefit from the knowledge and on-site presence of distinguished
medical experts who might otherwise be inaccessible.
Our support to this first-time competitive VP Program for Latin America, reflects our commitment to improve
outcomes for patients with advanced prostate cancer and to advance research, innovation, clinical expertise, and

education for healthcare professionals in Latin America.
The goals of this program are to provide meaningful practice-based educational experiences for oncology-care
teams in Latin America, building capacity in Latin American cancer medicine by identifying gaps in patient care and
assisting with solutions, and building global collaborations between Latin American and Western oncology care
professionals.
II. Eligibility
Geographic Scope: Argentina, Brazil, Chile, Colombia and Mexico.
Institutions Eligibility • Applicant (Principal Investigator; PI) must have a medical degree
Criteria: (MD, MBBS, or equivalent), and hold a position as a medical
oncologist seeing patients with prostate cancer in the respective
market.
• Principal Investigator should serve as Chair of the proposed VP
two-day medical education program.
• Applicants must be from healthcare/medical organizations that
provide comprehensive medical care for patients with advanced
prostate cancer, located in Argentina, Brazil, Chile, Colombia, or
Mexico.
• The institution and medical hosting team must be based in the
scoped Countries.
• Only institutions / organizations / associations are eligible to receive
Grants, not individuals or medical practice groups.
• Institutions applying for this grant must have proven oncology-care
capacity to host this Visiting Professorship.
• The project can involve multiple departments within an institution
and/or between different institutions / organizations / associations.
In this case all institutions must have a relevant role and the
requesting organization must have a key role in the project.
• The project/program lead must be an employee or independent
contractor of the requesting organization.
• Requesting organization must be legally able to receive award
funding directly from Pfizer Inc. We strongly recommend that
applicants confirm this with their organization or institution prior to
submitting an application. Grants approved to organizations that
are subsequently found to be unable to accept funding directly
from Pfizer Inc. may be subject to rescission.

III. Requirements
Date RFP Issued: February 8, 2024
Clinical Area: Oncology – Genitourinary – Prostate Cancer
Area of Interest for
The intent of this Request for Proposal (RFP) is to invite academic
this RFP:
oncology health institutions to submit applications to host a two-day
medical education program at the organization, to be led by two Visiting
Professors with expertise matched to the organization’s unmet educational
needs surrounding the management of advanced prostate cancer.
Application proposals from Organizations interested in hosting this
program must include but not limited to the following information:
• Description of Organization’s mission, vision, impact, and
reach. This includes statistics and descriptions of the following:
• Mission and Vision.
• Numbers of hospitals and clinics in organization; regional
reach and coverage.
• Numbers of patients served and patient visits.
• Numbers of hospital staff, including all employees, clinical
faculty, registered nurses, medical residents and fellows,
medical students, and academic faculty and students.
• Prevention, screening, diagnosis, and treatment services,
certifications and specialties.
• Clinical trials.
• Educational platforms and programs.
• Any innovation or research breakthroughs.
• Description of the Organization’s medical gaps, unmet needs,
challenges, and questions surrounding the management of
patients with advanced prostate cancer, for which a Visiting
Professor could provide education. Relevant clinical information
for the development of the program may include but is not limited
to:
• Training needs of the healthcare team including physicians,
nurses and other allied health professionals.
• Cancer care disparities that can be impacted with this
program.
• Treatment algorithm or sequencing challenges.
• Agenda for a two-day medical education program that should
include but is not limited to:
• Description of desired expertise from two out-of-country
physicians (“Visiting Professor”) representing different

medical disciplines (e.g., urology, medical oncology,
radiation oncology, nuclear medicine, radiology,
survivorship, etc.)
• Example agenda for meetings during two-day program
including a combination of lectures, patient case reviews,
informal discussions, and other meaningful interactions with
the local care team that would be facilitated. This Program
is expected to be held in English due to the International
Visiting Professors but can have simultaneous translation to
Spanish or Portuguese if needed (costs can be reflected in
the operational budget).
• Expected number of health care professionals attending this
Program (e.g., own site physicians, invitees from satellite
oncology sites or allied healthcare institutions, etc.)
• Expected local faculties, speakers, etc.
• Budget template for all local costs that can include, meeting
rooms, AV, local onsite management, local faculty fees, onsite
logistics, planning and staffing, simultaneous translation, not to
exceed $30,000 USD. Travel expenses and honoraria for the
Visiting Professors will be covered directly and should not be
included in the budget.
• Expected / desired results and outline of 12-month outcome
metrics for Visiting Professorship Program that will report on
enduring changes that have occurred in improvements in
patient care and physician education/knowledge. A 30-day
report on activities and outcomes that occurred during the Visiting
Professorship Program will also be required. This report can
include but is not limited to details on:
• Impact on patient management and outcomes
• Impact on physician education and knowledge
• Sustainability of practice changes
• Potential replicability and dissemination
• Collaborations with other oncology sites, medical societies,
academia, etc.
• Publications and/or communications plan
Target Audience: Medical oncologists should serve as Principal Investigator (PI) and
Program Chair, but all other medical disciplines can be included in the Program
plan, such as: radio-oncologists, allied prostate cancer healthcare
providers, and urology, pathology and nuclear medicine MDs.

Expected
• Individual Grant amounts will be up to $30,000 USD to cover for
Approximate
local costs related to this program.
Monetary Range of
Grant Applications: • Please note: PCF will select two international Visiting Professors
based on the approved program and its knowledge gaps. Travel
expenses and honoraria for the Visiting Professors will be
covered separately and are not part of this Grant budget.
• Approximately five sites will be supported by this educational
program.
• Applications will be reviewed by an expert review panel (ERP)
• The amount of the award will depend upon the expert review
panel’s evaluation of the proposal and costs involved and will be
stated clearly in the award agreement.
Key Dates:
• RFP release date: February 8, 2024
• Grant Application due date: April 4, 2024. Please note the
deadline is 23:59 Eastern Time (New York, GMT -5).
• Review of applications by ERP: May 2024
• Anticipated Grant Award Notification Date: June 2024
Grants will be distributed following a fully executed agreement.
• Anticipated Project Start and End Dates: July 1, 2024, to
July 31, 2025
How to Apply: Note: Please read this section carefully since applications submitted not
following these instructions will not be accepted and will be cancelled.
• Please go to https://www.cybergrants.com/pfizer/knowledge and
sign in. First-time users should click "Create your password”.
[Note: there are individual portals for each grant application
type. Please be sure to use the URL above.]
• In the application:
• For the question “What type of request are you
submitting?” select “Support for a Visiting Professorship”.
• For the question “Are you replying to a Request for
Proposal as part of the Competitive Grant Program?” select
Yes
• Select the following Competitive Grant Program Name:
2024 ONC LATAM Improving Advanced Prostate
Cancer Management in Latin America IME.
• Select the following Primary Area of Interest: Oncology –
Genitourinary - KG; Select Genitourinary – Prostate
for the Cancer Type Detail question.
• Requirements for submission:
• Complete all required sections of the online application and

upload your project proposal in the Proposal/Protocol field.
• If you encounter any technical difficulties with the website, please
click the “Technical Questions” link at the bottom of the page.
IMPORTANT: Be advised applications submitted after the due date will
not be reviewed.
Questions: If you have questions regarding this RFP, please direct them in writing to
Miguel Briceno (Miguelangel.briceno@pfizer.com) at with the subject
line: 2024 ONC LATAM Improving Advanced Prostate Cancer
Management in Latin America IME.
Grant Agreements: • If your Grant application is approved, your Institution will be
required to enter into a written grant agreement with Pfizer. Please
click here to view the core terms of the agreement.
• Pfizer has drafted the terms of these agreements to be balanced
and reasonable and to further the goals of both parties.
Negotiating grant agreements requires significant resources, so
please ensure that your institution (including your legal
department) is able and willing to abide by these terms before
proceeding with submission of your application as they will need
to be accepted in their entirety.
• Under Pfizer's competitive grant program, modifications to grant
agreements will not be reviewed unless a genuine conflict exists
as between applicable law and the terms of the relevant grant
agreement. Applicant is encouraged to share the core terms with
counsel for approval prior to submitting an application.
• Except where prohibited by applicable local laws or regulations
and, in any case, subject to review by Pfizer Legal, payment of
grant funding may only be paid to the grantee organization in its
country of domicile.
• This RFP is supported by Pfizer Inc. and, if approved, payment
will be sent from the United States.
Review and Approval • Grant requests received in response to a specific RFP are
Process: reviewed by an expert review panel (ERP) to make final grant
decisions.
• The panels are comprised of professionals from the medical
community with advanced degrees and expertise in particular
clinical areas, or specific needs of a geographic region/learner
group, or expertise in research, continuing professional
development or quality improvement.

Mechanism by which
• All applicants will be notified via email by the dates noted above.
Applicants will be
Notified: • Applicants may be asked for additional clarification during the
review period.